This inventor holds 1 USPTO granted patent. Top assignees: Abgenomics International Inc., Bioalliance C.v.. Active years: 2018.
Company Filing History:
1 out of 5 
1 out of 10 Years Active: 2018
Title: Li-An Hu: Innovator in Antibody-Drug Conjugates
Introduction
Li-An Hu is a prominent inventor based in Taipei, Taiwan. He has made significant contributions to the field of cancer treatment through his innovative work on antibody-drug conjugates. His research focuses on enhancing the efficacy of cancer therapies, which has the potential to improve patient outcomes.
Latest Patents
Li-An Hu holds 1 patent for his invention titled "Anti-folate receptor alpha (FRA) antibody-drug conjugates and methods of using thereof." This patent provides a novel approach to cancer treatment by utilizing anti-folate receptor alpha (FRA) antibody-drug conjugates that incorporate a hydrophilic self-immolative linker. The methods and compositions disclosed in this patent aim to offer new therapeutic options for patients battling various cancers.
Career Highlights
Throughout his career, Li-An Hu has worked with notable companies in the biotechnology sector. He has been associated with Abgenomics International Inc. and Bioalliance C.V., where he has contributed to advancing cancer treatment technologies. His expertise in the field has positioned him as a key player in the development of innovative therapeutic solutions.
Collaborations
Li-An Hu has collaborated with esteemed colleagues, including Feng-Lin Chiang and Shih-Yao Lin. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and advancements in cancer research.
Conclusion
Li-An Hu's work in developing antibody-drug conjugates represents a significant advancement in cancer treatment. His innovative approach and dedication to research continue to inspire progress in the field.